Research
Topics:
INDEX
MCS 1
PRIME 34
PRIO 4
aging 17
ai-chat 3
body 1
brain 21
brainwave 7
cancer 14
censorship 1
climate 1
cognition 7
computers 1
covid-19 1
crime 2
culture 7
dental 1
diabetes 9
drugs 3
ears 1
economy 8
election 2
energy 1
exercise 4
eyes 4
genetics 3
gut 4
heart 15
immune 4
kidneys 6
law 1
lungs 2
metabolism 6
microbiome 5
misc
ms 1
music 1
nutrition 12
obesity 4
pain 6
politics 5
pollution 2
population 1
practice 4
psychology 11
religion 3
reproduction 8
rights 3
sleep 2
soc-media
stress 1
tech 3
vaccine 1
virus 1
war-conflict
war-cyber 2
 
Scanned: 1708
Evaluated: 630
Selected: 127

 
Back Issue Map
    CANCER    IMMUNE    VACCINE   

Mca46-004

OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study

Quote: Patients with SD had significantly higher anti-survivin antibody titres than those with progressive disease (PD) (p0.0418). OVM-200 was well tolerated and induced robust survivin-specific immunity, providing clinical evidence that it can break immune tolerance to self-antigen survivin and supporting further development. ClinicalTrials.gov identifier: NCT05104515.
Article: https://www.medrxiv.org/content/10.64898/2026.11.08.26367556v1
Search Similar: Mojeek Startp Brave Bing Googl Lycos Utub Yahoo 
Search Authors: Peter Kok-Ting Wan Thomas Morris Martin D. Forster Tianen Zhang Michael Flynn Florence Chamberlain Mark Tuthill Fiona Thistlethwaite Anja Williams William Finch Wenshu Lu Shisong Jiang, 

  Javilk's Research Links Newsletter for Week 46
Updated 11/21/2026-03:41:55 AM
Back Issue Topic Map
What interests you? What have you found? Tell me!
Drop me a note at Javilk.com to subscribe or submit something.